Shares in Grail jumped after the FDA posted documents ahead of an advisory committee meeting on its mult-cancer blood test, Galleri, signaling the agency may take a favorable view. The panel meeting is scheduled for Wednesday and will include expert discussion; while the FDA is not required to follow the panel’s advice, it often does. Galleri is already available as a laboratory-based diagnostic, but an FDA approval pathway could shift reimbursement prospects, including potential Medicare and insurer coverage decisions. The stock movement suggests investors are treating the meeting materials as a key near-term catalyst. Separately, another report emphasized that the FDA’s briefing package is expected to shape the committee discussion, even as the agency retains final discretion on the ultimate regulatory outcome.